Rhythm Pharmaceuticals Launches IMCIVREE in Japan After NHI Listing
IMCIVREE is approved in Japan for acquired hypothalamic obesity and is included on the NHI drug price list. It is the first approved therapy in Japan for the condition.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.